Our objective was to identify preventable adverse drug events and factors contributing to their development.
Prospective studies indicate that between 28 and 80% of adverse drug events are preventable. [8] [9] [10] [11] [12] [13] [14] [15] Most studies describe the type and severity of preventable events, 8, 10, [15] [16] [17] [18] [19] without identifying highimpact patient populations, system-level targets for intervention, or the contexts in which preventable events occur. 2, 7, 15, 17, [20] [21] [22] [23] Some preventability assessment methods have made broad assumptions in assessing preventability. 24 For example, one algorithm automatically assumes that all adverse drug events due to medications amenable to monitoring using laboratory testing can be averted by increasing the frequency of laboratory monitoring. 24 However, it is possible that increasing the frequency of routine laboratory monitoring without understanding contextual or contributing factors risks being ineffective while unnecessarily increasing resource utilization.
Our main objective was to describe the characteristics of preventable adverse drug events experienced by patients presenting to emergency departments with an adverse drug event. Our secondary objective was to highlight factors that contributed to their development. 
| METHODS

| Population
We reviewed the medical and/or research records of all patients who had been diagnosed with one or more medication-related problems or adverse drug events in one of three prospective multi-centre parent studies conducted by our research group (Appendix A). 4, 5, 25, 26 The first parent study, conducted in 2008-2009, derived a clinical decision rule to identify patients at high-risk of adverse drug events from 1 591 patients presenting to the emergency departments of two tertiary care hospitals, Vancouver General (VGH) and St. Paul's Hospitals (SPH), in Vancouver, British Columbia, Canada. 5 In this study, 226 of the enrolled patients were diagnosed with an adverse drug event. This parent study was approved by the UBC Clinical Ethics Board. The second parent study, conducted in 2011-2013, evaluated the impact of pharmacist-led medication review on health outcomes from 10 807 patients presenting to the emergency departments of VGH, Lions Gate Hospital (LGH), an urban community hospital in North Vancouver, British Columbia, and Richmond General Hospital (RGH), an urban community hospital in Richmond, British Columbia. 4 In this study, patients at high risk of adverse drug events based on the clinical decision rule derived and validated in the other two parent studies were systematically selected for medication review (Appendix A). Of these patients, 2862 were diagnosed with medication-related problems. The need for ethics review for this study was waived as this was a quality improvement project. The third parent study, conducted in 2014-2015, validated the previously derived clinical decision rules using 1 529 patients presenting to the emergency departments of VGH, LGH and the Ottawa Civic Hospital (OCH), an urban tertiary care hospital in Ottawa, Ontario, Canada. 25 In this study, 240 of the enrolled patients were diagnosed with an adverse drug event. This parent study was approved by the UBC Clinical Ethics Board. All three studies systematically enrolled patients presenting to an emergency department (Appendix B). In the three parent studies, clinical pharmacists and physicians evaluated all enrolled patients at the point-ofcare, and documented medication-related problems or adverse drug events in research and medical records. All cases in which the clinical pharmacist and physician diagnoses were concordant were considered
final. An independent committee adjudicated all cases in which their assessments were discordant or uncertain.
The current study was conceived after the completion of these three prior studies, as the parent studies had allowed us to compile a large database of prospectively identified adverse drug events. We reviewed the research records and/or medical records of the hospital that all participants diagnosed with a medication-related problem or adverse drug event presented to in the primary studies, and used charts to exclude patients no longer meeting our case definition of adverse drug event for the current study (Appendix C), or who had been diagnosed with an alternative diagnosis since the conclusion of the parent study. We excluded patients whose research and medical records could not be retrieved, and those with illegible records. 4, 5, 25, 26 What is already known about the subject • Adverse drug events represent a major burden on the healthcare system.
• Efforts to reduce adverse drug events should focus on preventable events and consider factors that contribute to their development.
What this study adds
• More than two-thirds of adverse drug events were rated as probably or definitely preventable.
• Patients with mental health conditions, diabetes, and those receiving high-risk medications (i.e., warfarin, hydrochlorothiazide, furosemide, insulin and acetylsalicylic acid) were at increased risk of experiencing a preventable adverse drug event.
• Contributing factors commonly included inadequate patient instructions, monitoring and follow-up, and reassessments after medication changes had been made.
| Definitions
We defined adverse drug events as harm caused by a drug or the inappropriate use of a drug, consistent with its effective definition in clinical practice. 27 Adverse drug events included adverse drug reactions, undesirable effects to drugs occurring within the normal therapeutic range, 28, 29 drug interactions, supra-and sub-therapeutic doses, events due to non-adherence or inappropriate drug withdrawal, and cases in which the patient was on an ineffective or on no drug despite previous documentation of an indication for and lack of contraindication to the drug (e.g., a patient presenting with an ischaemic stroke with a previously documented history of atrial fibrillation and a high stroke risk but no anticoagulation). 19 For events presenting with abnormal vital signs, we defined cut-offs a priori, excluding all other cases (Appendix B).
For events involving laboratory abnormalities, we used the reference values of each participating hospital. We categorized severity as mild when the adverse drug event required no change in medical management, moderate when it required a change in medical management, and severe when it was either the primary reason for hospitalization, caused permanent disability, or proved fatal.
Based on our findings from previous work, we considered adverse drug events as preventable when there was "lack of adherence to best medical practice, including inappropriate drug, dosage, route or frequency of administration of a drug for the patient's clinical condition, age, weight or renal function; administration of a drug despite a known allergy, a previous adverse reaction to, or a drug interaction; non-adherence; laboratory monitoring not or inappropriately performed; prescribing or dispensing errors, or errors in drug administration." 30 We defined contributing factors as any patient-, provider-or system-level factors that our reviewers deemed instrumental to the development of the event.
| Chart review methods
After excluding cases that did not meet our case definition, a clinical pharmacist (S.W.) and physician (one of C.H., D.V. or F.S.) reviewed the medical and/or research records of all patients diagnosed with one or more adverse drug events, and independently assessed each event's preventability. Events were categorized as definitely, probably or not preventable. 30 If preventability ratings were discordant, reviewers discussed the case until reaching consensus, and a third 
| Statistical analysis
We conducted descriptive analyses on baseline demographics for all included patients. We calculated the proportion of preventable adverse drug events as the number of definitely and probably 
| RESULTS
We reviewed the charts of 3 202 patients, of whom 1 234 were diagnosed with at least one adverse drug event ( Figure 1 ). Among these patients, 809 (65.6%) were diagnosed with one or more preventable events ( supratherapeutic dosing (13.6%) were most common, while among non-preventable events adverse drug reactions (54.8%), low dose (11.9%) and ineffective drugs (11.7%) were more common ( Table 3) .
Adverse drug events due to non-adherence were more likely to be considered preventable (28.2%) vs non-preventable (3.1%; P < 0.01; Table 3 ). In contrast, a lower proportion of the preventable ADEs were adverse drug reactions (23.8%) compared with the nonpreventable ADEs (54.8%; P < 0.01; Table 3 ). Severe adverse drug events and those resulting in permanent harm or death were equally common between preventable and non-preventable events, but preventable events had a higher proportion of patients who suffered no harm compared to non-preventable events ( Table 3) .
The most common medications associated with preventable adverse drug events were warfarin (9.4%), hydrochlorothiazide (4.5%), furosemide (4.0%), insulin (3.9%) and acetylsalicylic acid (2.7%; Table 5 ). Common barriers to adherence included mental health illness (6.8%) and patient preference (6.3%; Table 5 ).
| DISCUSSION
We sought to describe preventable adverse drug events from outpatient medications among adults presenting to emergency departments. Almost two-thirds of adverse drug events diagnosed in the emergency department were preventable. Patients with mental health conditions and diabetes were more likely to experience preventable events, while older patients were not. Atypical antipsychotics and thiazide diuretics were more commonly associated with preventable events, while other medication classes commonly targeted in preventative efforts, such as coumarin derivatives and anti-infectives, were not associated with preventable events. 31, 32 Insufficient education and monitoring commonly contributed to preventable events.
Current efforts in adverse drug event prevention often target specific patient populations, such as the elderly, or those taking medication classes such as anticoagulants that are commonly associated with adverse drug events, regardless of their preventability. [32] [33] [34] Many adverse drug events experienced by older adults may not be preventable, given the complexities of their medication regimens. 35 This is in keeping with systematic reviews that have indicated that medication reviews in older patients may increase adherence and drug knowledge, without resulting in improvements in patient-oriented or system-level outcomes such as reduced hospitalizations and emergency department visits. 26, 36 Developing strategies that specifically target patients and medications associated with preventable events may be an effective alternative.
Understanding contributing factors to preventable events can provide insight into why the adverse drug events occurred. Previous studies have recommended steps to improve patient adherence, encourage provider adherence to guidelines, increase diligence in monitoring patients, and optimize communication between providers and patients. 19, 23, 31, 37 Others have highlighted inappropriate prescribing practices and insufficient monitoring of medications as contributing factors. 38, 39 In a systematic review, identifying over-treated patients with diabetes and de-intensifying therapy was associated with reduced hypoglycaemic events without compromising glycaemic control. 40 Our findings support these conclusions, and highlighted the importance of enhanced monitoring for patients on thiazide diuretics and insulin, as these medications were commonly implicated in preventable events. Specifying medications at highest risk of preventable adverse drug events may assist in developing more specific recommendations to enhance the feasibility of and reduce the resource utilization associated with enhanced monitoring. Similarly, focusing resources to promote better education and monitoring for high-risk non-adherent patients may be advantageous. 41, 42 For example, additional resources for mental health patients may include access to intense case management, a team-based model of care providing educational and environmental support to help patients remain adherent to medications. 42, 43 Our study is not without limitations. While our study was multicentre and conducted in two provinces, most cases were enrolled in British Columbian urban hospitals. Our results may therefore not be representative of the types of adverse drug events seen in other jurisdictions or contexts.
Our retrospective assessments of preventability and contributing factors were limited by the availability of the information documented in research records and/or paper-based and electronic medical records. It was often difficult to assess the preventability of an event without knowing the exact circumstances of the care that had been provided, or the patient's perspective. Individual and professional biases may have affected how reviewers perceived the preventability of an event. 30, 44 Not all contributing factors were explicitly documented in the research or medical records, and therefore, undoubtedly, our clinical judgement, the patient's prior history, and documentation of the event's resolution informed our assessments.
We assumed that if a clinician had addressed the contributing factor prior to the event, the event would have been prevented. To increase the thoroughness and reduce the subjectivity of our preventability assessments, a second reviewer independently assessed the preventability of an event to produce a more robust assessment. However, this was not possible for the assessment of contributing factors, due to budgetary and time constraints.
Many contributing factors could be attributed to multiple nonexclusive domains. Often, the charts provided insufficient information to attribute a contributing factor to any one single domain, and might be attributable to more than one domain (e.g., communication could be a provider-level, patient-level or system-level issue). Given that prospective assessment and study of contributing factors is not feasible (it is not ethical to identify and observe contributing factors without intervening), this is a limitation inherent to this body of work.
In conclusion, efforts to reduce adverse drug events should focus on preventable adverse drug events and address common contributing factors. Our work suggests that close monitoring of patients with mental health conditions and diabetes is warranted. In addition, enhanced laboratory monitoring is indicated specifically for patients on insulin and thiazide diuretics. "Harm caused by the use of a drug."
• The sign(s) or symptom(s) are generally not deemed to have an alternate explanation by the pharmacist and the treating physician.
In cases where alternative causes are possible (e.g., fall), the event should only be considered a suspect adverse drug event, if it is likely that the symptom would not have been as severe or not have occurred without the patient being on the drug (e.g., intracranial haemorrhage).
• Abnormal vital signs may constitute an adverse drug event, if the abnormal vital signs meet the cut-offs below, and treating the adverse drug event is medically appropriate according to the treating physician:
HR ≤ 50 and associated with symptoms (e.g., presyncope/syncope, prolonged sinus pauses on ECG)
HR ≥ 120 and associated with symptoms (e.g., presyncope/syncope, chest pain or palpitations) BP ≥ 180 SBP or ≥ 100 DBP
• Abnormal laboratory tests can be considered an adverse drug event if they are outside of the hospital's reference range, and treating the adverse drug event is medically appropriate according to the treating physician.
• Harm caused by the use of alcohol or illicit drugs does not constitute an adverse drug event.
ADE classification:
Adverse drug reaction (ADR): "A response to a drug that is noxious and unintended, and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease".
Drug interaction.
Dosage Too High.
Dosage Too Low.
Non-adherence.
Inappropriate Drug Withdrawal.
Ineffective Drug.
Needs Additional Drug/Untreated Indication: This categorization
should be reserved for cases in which there is clear previous documentation (i.e., before the index ED visit) in the patient's records about a hard indication for the drug, and lack of contra-indication for treatment.
Transcription/Dispensing/Administration Error.
ADE severity:
Fatal: The adverse event resulted in death.
Severe:
The adverse drug event was the primary reason for the patient's hospitalization, caused permanent disability or was lifethreatening.
Moderate:
The adverse event required a change in medical management (medical therapy, a diagnostic procedure or consultation).
Mild:
No change in medical therapy, including no adjustment of medications required.
ADE preventability:
Preventable if: there is a lack of adherence to best medical practice, including inappropriate drug, dosage, route or frequency of administration of a drug for the patient's clinical condition, age, weight or renal function; administration of a drug despite a known allergy, a previous adverse reaction to, or a drug interaction; non-adherence; laboratory monitoring not or inappropriately performed; prescribing or dispensing errors, or errors in drug administration.
